IMUX supply chain intelligence for Immunic, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Immunic, Inc. (IMUX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| B-RILEY-SECURITIES | B-RILEY-SECURITIES | 90% | Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents… |
| BROOKLINE-CAPITAL-MARKETS | BROOKLINE-CAPITAL-MARKETS | 90% | Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents… |
| DAIICHI-SANKYO-CO-LTD | DAIICHI-SANKYO-CO-LTD | 90% | During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. |
| GUGGENHEIM-SECURITIES | GUGGENHEIM-SECURITIES | 90% | Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents… |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 90% | Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents… |
| LIFESCI-CAPITAL | LIFESCI-CAPITAL | 90% | Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents… |
| STIFEL | STIFEL | 90% | Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents… |
| WILLIAM-BLAIR | WILLIAM-BLAIR | 90% | Leerink Partners LLC, Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as placement agents… |
| BVF-PARTNERS-L-P | BVF-PARTNERS-L-P | 80% | On February 12, 2026, the Company entered into a purchase and sale agreement (the "Royalty Purchase Agreement") with certain Series B Warrant holders who had purchased a predetermined number of Serie… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AMERICAN-CAPITAL-PARTNERS-LLC | AMERICAN-CAPITAL-PARTNERS-LLC | 62% | llion increase related to personnel expenses, of which $1.8 million was related to non-cash stock compensation, (ii) a $0.2 million increase in legal and consultancy expenses, (iii) a $0.2 million in… |
| DAIICHI-SANKYO-CO-LTD | DAIICHI-SANKYO-CO-LTD | 62% | associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurr… |
| GLIOMIC-THERAPEUTICS-INC | GLIOMIC-THERAPEUTICS-INC | 62% | s ("RRMS"), progressive multiple sclerosis (”PMS”) and other diseases; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could poten… |
| IMMUNIC-AG | IMMUNIC-AG | 62% | at such bonus will be determined by the Company in the ordinary course and will be paid (to the extent determined to have been earned by the Company) when such bonus is paid to employees of the Compa… |
| IMMUNIC-AG-IMMUNIC-AUSTRALIA-PTY-LTD | IMMUNIC-AG-IMMUNIC-AUSTRALIA-PTY-LTD | 62% | s ("RRMS"), progressive multiple sclerosis (”PMS”) and other diseases; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could poten… |
| IMMUNIC-AUSTRALIA-PTY-LTD | IMMUNIC-AUSTRALIA-PTY-LTD | 62% | s ("RRMS"), progressive multiple sclerosis (”PMS”) and other diseases; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could poten… |
| IMMUNIC-GMBH | IMMUNIC-GMBH | 62% | associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurr… |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | llion increase related to personnel expenses, of which $1.8 million was related to non-cash stock compensation, (ii) a $0.2 million increase in legal and consultancy expenses, (iii) a $0.2 million in… |
| SVB-LEERINK-LLC | SVB-LEERINK-LLC | 62% | 023. Warrants and Tranche Rights The Company accounts for issued financial instruments either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with… |
| TITAN-PARTNERS-GROUP-LLC | TITAN-PARTNERS-GROUP-LLC | 62% | llion increase related to personnel expenses, of which $1.8 million was related to non-cash stock compensation, (ii) a $0.2 million increase in legal and consultancy expenses, (iii) a $0.2 million in… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IMUX-DEBT-10256 | Warrants outstanding: 3719.6 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| IMUX-DEBT | Debt stack $146,000 | 90% | Market cache reports total debt of $146,000. |
| IMUX-DEBT-10257 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-12-31. |